Carregant...
NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer
Small cell lung cancer (SCLC) is a high-grade malignancy, and treatment strategies have not changed for decades. In this study, we searched for novel targets for antibody-drug conjugate (ADC) therapy for SCLC. We identified transmembrane proteins overexpressed specifically in SCLC with little or no...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7533074/ https://ncbi.nlm.nih.gov/pubmed/33062195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27718 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|